Fresenius commits to more PROSORBA columns:
This article was originally published in Clinica
Cypress Bioscience has secured further orders from Fresenius Medical Care North America for its PROSORBA column in an expansion to Fresenius' pilot programme of the FDA-approved device. The PROSORBA reduces symptoms in moderate to severe rheumatoid arthritis in hard-to-treat patients. Fresenius has bought a further 1,000 units and will buy a similar number in the third and fourth quarters to support the pilot doctor's office study and hospital use.